1Chertow GM,Burke SK,Raggi P,et el.Sevelamer attenuates the progression of coronary and aortic cardiovascular calcification in he modialysis patients[J].Kidney Int,2002,62(1):245-252.
2Wilson PW,Kauppila LI,ODonnell CJ,et al.Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality[J].Circulation,2001,103(11):1529-1534.
3National Kidney Foundation.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease[J].Am J Kidney Dis,2003,42(4 Suppl 3):S1-201.
5London GM,Marchais SJ,Guerin AP,et al.Arterial structure and function in end-stage renal disease[J].Nephrol Dial Transplant,2002,17(10):1713-1724.
6Quarles LD,Sherrard DJ,Adler S,et al.The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease[J].J Am Soc Nephrol.2003,14(3):575-583.
7Strozecki P,Adamowicz A,Nartowicz E,et al.Parathormon,calcium,phosphorus,and left ventricular structure and function in normotensive hemodialysis patients[J].Ren Fail,2001,23(1):115-126.
6Epstein S,Traberg H,Raja R,et al.Serum and dialysate osteocalcin levels in hemodialysis and peritoneal dialysis patients and after renal transplantation.J Clin Endocrinol Metab,1985,60:1253-1256.
7Weiss LG.Clinical aspects and applications of hemofiltration.Scand J Urol Nephrol ,1989,Suppl 118:1-64.
8Lepenies J,Stahl C,Ludat K,et al.Elimination of leptin by different extra corporeal treatment modalities.Nephrol Dial Transplant,2000,15:220.
3Urena-Torres P,Metzger M,Haymann JP,et al.Association of Kidney function,vitamin D deficiency,and circulating markers ofmineral and bone disorders in CKD [J].Am JKidney Dis,2011,58:544-553.
4Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the pro- gression of coronary and aortic calciication in hemodialysis pa- tients[J].Kidney Int 2002,62: 245-252.
5Dyer, Christopher A.Safety and tolerability of paricalcitol in pa- tients with chronic kidney disease[J].Expert Opinion on drug safety,2013,12(5) : 717 -728.
6G.Jean, T.Vanel, et al.Prevention of secondary hyperparathy- roidism in hemodialysis patients:The key role of native vitamin D supplementation[J].Hemodialysis International,2010,14(14): 486-491.
7Eid M E1-Shafey,Ali E Alsahow,et al.Cinacalcet Hydrochloride- Therapy for Secondary Hyperparathyroidism in Hemodialysis Pa- tients[J].TherapeuticApheresis and Dialysis TherapeuticAphere- sis and Dialysis 2011,15(6):547-555.
8Conzo G,Perna AF,Impaet of parathyroideetomy on cardiovascu- lar outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cas- es prior to the calcimimetics era[J].BMC Surgery,2013,13(2):S4.
